04-01-2011: Merck KGaA announced that it will sell its Crop BioScience business, which is part of the Performance Materials division, to Novozymes A/S, Denmark for a total consideration of USD 275 million. The agreement is subject to customary regulatory approvals. Closing of the transaction is expected in beginning of 2011.
Merck’s divested Crop BioScience business researches, develops and commercializes technologies used to improve plant health and crop yields. These activities are carried out in North and South America through three dedicated legal entities: EMD Crop BioScience, Milwaukee, USA; EMD Crop BioScience Canada; and Merck Crop BioScience Argentina. The Crop BioScience business generated about EUR 35 million of sales in 2009 and employs approximately 165 people.
“With the acquisition of Millipore the strategic focus of Merck’s Chemicals business significantly changed towards the life science industries. The Crop BioScience business is focused on a specific segment within the agricultural industry and has very limited overlap with other parts of Merck’s business,” said Bernd Reckmann, member of the Executive Board of Merck. “Under the leadership of an experienced and highly motivated management team, the Crop BioScience business has shown very strong growth over the past several years. I firmly believe that as an established player in the agricultural biologicals industry, Novozymes will be able to take the business to the next level.”
“The acquisition of Crop BioScience strengthens our global position in the growing industry for agricultural biologicals providing products that enhance the natural growth and yield of crops,” said Steen Riisgaard, CEO of Novozymes. “We have found in Crop BioScience a company that has a strong strategic fit with our existing BioAg business. In brief, it has a complementary product range and geographical scope, a strong R&D pipeline, and very talented people. Together we can utilize Novozymes’ unique biotechnology platform to bring a new level of innovation to the market.”
The Crop BioScience business joined Merck in 1991 with the acquisition of Lipha. It was expanded with the acquisition of Agribiotics (Canada) in 2006. Merck’s Crop BioScience business researches, develops and commercializes crop-enhancing products for on-seed, foliar and in-furrow applications for soybeans, pulses, forage crops, peanuts, corn and alfalfa. These products improve root development, plant health and yield. Many of the lead products such as Optimize® for soybeans and Torque™ IF for corn contain its patented LCO Promoter Technology® - a naturally-occurring molecule that brings unprecedented early-season vigor and plant health benefits to a number of crops.
Merck Serono announced that based on its recent analysis of the human growth hormones (HGH) market, Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Award.
“Merck Serono is lauded for its cutting-edge drug delivery devices - easypod® and cool. ... more
Merck Serono announced the creation of Calypso Biotech, the sixth spin-off company resulting from its Entrepreneur Partnership Program (EPP). Calypso Biotech was formed around Merck Serono’s R&D portfolio in the field of inflammatory bowel diseases, targeting selected niche indications with ... more
Merck announced that the Phase III CENTRICa trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). CENTRIC includ ... more
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Th ... more
Merck Schuchardt OHG, a 100% subsidiary of Merck KGaA, Germany, has, for the last 135 years, been one of the leading German producers and suppliers of organic intermediates, fine chemicals, reagents and
solvents for laboratories, medium-sized and bulk production. more
Together EMD Biosciences and Merck Chemicals Ltd. are the research reagents group of the Performance and Life Science Chemicals division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has more than 29,000 employees in 53 countries. more
Novozymes and Terranol, a Denmark-based biotechnology company specialized in yeast, announced an agreement that will ensure the final optimization of the Terranol C5 yeast strain and give Novozymes the rights to register and market Terranol’s C5 yeast technology. C5 yeast is an essential co ... more
BASF, Cargill and Novozymes have signed an agreement to develop technologies to produce acrylic acid from renewable raw materials.Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil. BASF, Cargill and Novozymes will develop bio-based tech ... more
Novozymes has succeeded in developing a fungus that enables production of malic acid from renewable raw materials instead of oil. Malic acid is used as a flavor enhancer in the food industry and can be converted into other chemical derivatives used for a variety of plastic, polymer and resi ... more
Novozymes is the world leader in bio-innovations. Together with customers across a broad array of industries, we create tomorrow's industrial bio-solutions, which both improves our customers' business and the use of the planet's resources more